home / stock / autl / autl articles

AUTL Articles, Autolus Therapeutics plc

Stock Information
Company Name: Autolus Therapeutics plc
Stock Symbol: AUTL
Market: NASDAQ
Menu
AUTL AUTL Quote AUTL Short AUTL News AUTL Articles AUTL Message Board
Get AUTL Alerts

News, Short Squeeze, Breakout and More Instantly...
Crude Oil Gains 1%; GameStop Shares Plunge | Benzinga

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 50 points on Friday. The Dow traded up 0.12% to 39,917...
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga

Shares of Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) fell sharply during Friday's session after the company reduced its dividend and...

Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday | Benzinga

U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday'...

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress | Benzinga

LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-gen...
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call | Benzinga

LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-gen...

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO | Benzinga

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-g...

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors | Benzinga

LONDON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-ge...
Autolus Therapeutics Announces Changes to its Board of Directors | Benzinga

-  Appointment of Elisabeth ("Lis") Leiderman, M.D. -  Resignation of Kapil Dhingra, M.D. LONDON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Autolus Th...

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 | Benzinga

Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/...

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023 | Benzinga

In-person and webcast event on Sunday, 10 December, 2023 at 8:00 AM PT / 4:00 PM GMT Review of pooled analysis of the ongoing FELIX Phase Ib/II s...
Next 10